These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12216532)

  • 21. [Enfuvirtide desensitisation: due to a failed case].
    López-de-Torre Querejazu A; Ibarra Barrueta O; Santos Ibañez A; Mayo Suárez J
    Farm Hosp; 2012; 36(2):112-3. PubMed ID: 22024011
    [No Abstract]   [Full Text] [Related]  

  • 22. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
    Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S
    J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 24. T-20: entirely new antiretroviral.
    James JS
    AIDS Treat News; 1997 Sep; (No 279):5-6. PubMed ID: 11364691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 26. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. T-20 salvage results hold up at 48 weeks.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):77-8. PubMed ID: 14666913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 28. The treatment pipeline: new therapies are on the way.
    Boyle BA
    AIDS Read; 1999 Nov; 9(8):519-20, 523-5, 528-9. PubMed ID: 11082727
    [No Abstract]   [Full Text] [Related]  

  • 29. Nailing down another HIV target.
    Richman DD
    Nat Med; 1998 Nov; 4(11):1232-3. PubMed ID: 9809537
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
    Cohen J
    Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
    [No Abstract]   [Full Text] [Related]  

  • 31. A T-20 diary.
    Gormley F
    GMHC Treat Issues; 2002 Mar; 16(3):6-7. PubMed ID: 12004799
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 33. New class of HIV drugs shows promise.
    Dove A
    Nat Med; 2001 Dec; 7(12):1265. PubMed ID: 11726950
    [No Abstract]   [Full Text] [Related]  

  • 34. David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
    Reddy D
    Lancet Infect Dis; 2003 Feb; 3(2):110-3. PubMed ID: 12560198
    [No Abstract]   [Full Text] [Related]  

  • 35. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-20: a model for novel anti-HIV drugs in development.
    Laurence J
    AIDS Read; 2002 Nov; 12(11):469-70. PubMed ID: 12494906
    [No Abstract]   [Full Text] [Related]  

  • 37. Enfuvirtide.
    LaBonte J; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 May; 2(5):345-6. PubMed ID: 12755128
    [No Abstract]   [Full Text] [Related]  

  • 38. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
    TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
    [No Abstract]   [Full Text] [Related]  

  • 40. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.